Navigation Links
Par Pharmaceutical Reports Third-Quarter 2007 Results
Date:12/20/2007

ion, respectively. Partially offsetting the increases were lower sales of certain existing products due to competitive pressures, including fluticasone, various amoxicillin products, quinapril, megestrol oral suspension, and doxycycline. Revenues of branded products for the third quarter of 2007 of $24.6 million, an increase of 72.5 percent over the prior year period, were driven by increased sales of Megace(R) ES (megestrol acetate) oral suspension, and fees related to the co-promotion of AndroGel(R).

Par's third-quarter gross margin was 31.2 percent of sales, compared to 31.6 percent in 2006. The Company's gross margin reflects the impact of increased metoprolol succinate ER sales, which have significantly lower gross margin percentages than many of the other products sold by the Company. This impact was offset by increased sales of higher margin products such as propranolol ER and Megace ES, lower inventory write-offs and reduced sales on other lower margin products, including fluticasone.

Research and development (R&D) expenses increased 161.0 percent for the third quarter 2007 compared with the third quarter 2006. The increase was due primarily to costs associated with the in-license of two Phase III products in support of the Company's branded division, Strativa. In July, the Company paid $15 million to BioAlliance Pharma for the US commercialization rights to Loramyc. In August, the Company acquired the North American commercial rights from Hana Biosciences, Inc. ("HANA") for Zensana(TM), at which time the Company made a $5.0 million equity investment in Hana at a contractually agreed premium. Of this amount, $1.2 million representing the premium paid was charged to R&D expense in the quarter. In support of the Company's generic business, Par made a $5.0 million equity investment in IntelliPharmaCeutics Ltd. (IPC), a privately held corporation, to develop and market four controlled release generic drug products. Of this amount, approximately $2.
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... According to the article published July 27 on ... courthouse was contained and extinguished by the city’s fire department before it caused major damage ... the time of the fire, and it was a fire alarm system that tipped off ...
(Date:7/31/2015)... ... , ... Cosmetic Town has proven itself as the leader ... procedures including, but not limited to, abdominoplasty, blepharoplasty, rhinoplasty and septoplasty. The ... , Staying up to date with the latest cosmetic trends has never ...
(Date:7/31/2015)... ... 31, 2015 , ... Creating one of the most modern fertility centers in ... image that goes beyond the boundaries of fertility medicine. , As the leading ... with dependable patient support, affordable treatments, unending hope, and high fertility success rates — ...
(Date:7/31/2015)... ... 31, 2015 , ... The Mount Sinai Health System will work with Columbia ... of related, experimental treatments. The collaboration moves into the next phase with the recent ... of five state licenses to produce and dispense medical marijuana. , Mount Sinai ...
(Date:7/31/2015)... Ohio (PRWEB) , ... July 31, 2015 , ... ... District Court for the Northern District of Ohio, Western Division (Case No. 3:15-cv-00397) ... (Case No: 3:15-cv-00397), the women experienced spontaneous migration of their Implanon® implants, inability ...
Breaking Medicine News(10 mins):Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 2Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 3Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3
... (Nasdaq: IDIX ) announced today that management will ... Healthcare Conference on Tuesday, March 10th at 1:30 p.m. ET ... and Company 29th Annual Healthcare Conference on Tuesday , ... Boston Marriott Copley Place.The live and archived webcasts of the ...
... First sugar-free, functional water brand made specifically for kids ... YORK, March 3 WAT-AAH!, the first sugar-free, functional ... their mothers, announces the first official "WAT-AAH! Challenge" to ... juice over water. During the month of March, mothers ...
... and 14th year of consecutive product revenue growth. ... support growing non-US business.Q4 2008 Highlights:- Product revenues ... 161% to $4.7 million - Over 31,700 Masimo ... were shipped in Q4 2008- International realignment results ...
... has surprising impact on young people GAITHERSBURG, Md., March ... of breakfast for students, Sodexo, a leading provider of ... districts across the country, has created a list of ... National School Breakfast Week, March 2-6."Studies repeatedly show that ...
... taking Plavix, PPIs have 25 percent increased chance of ... Heart attack patients given the blood thinner Plavix, plus ... may be at increased risk of death or another ... are given Plavix (clopidogrel) to help reduce the risk ...
... lead to consumer confusionWASHINGTON, March 3 As ... in the diet, it,s important that people understand ... studies, according to the Corn Refiners Association (CRA). ... fructose and high fructose corn syrup, creates factually ...
Cached Medicine News:Health News:Let Water Be Water, LLC Introduces New 'WAT-AAH! Challenge' 2Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 2Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 3Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 4Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 5Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 6Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 7Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 8Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 9Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 10Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 11Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 12Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 13Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 14Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 15Health News:Masimo Reports Fourth Quarter and Full Year 2008 Financial Results 16Health News:Sodexo Shares Top Breakfast Benefits for Students 2Health News:Blood Thinner, Heartburn Drugs May Be Risky After Heart Attack 2Health News:Blood Thinner, Heartburn Drugs May Be Risky After Heart Attack 3Health News:Pure Fructose Frequently Confused With High Fructose Corn Syrup 2
(Date:7/30/2015)... Calif. , July 30, 2015 IRIDEX ... will release its second quarter 2015 financial results after ...   In conjunction with the release, the Company will ... 5:00 p.m. Eastern Time on Thursday, ... the quarter and other business developments. Interested ...
(Date:7/30/2015)... 30, 2015  Unichem Pharmaceuticals ( USA ... Hydrochlorothiazide tablets 25 mg 1000-count bottle to the consumer ... measure due to the identification of a Clopidogrel tablet ... The risk associated with mistakenly taking a Clopidogrel ... probability of experiencing Clopidogrel,s side effects which include bleeding ...
(Date:7/30/2015)... -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ) ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... notice it received on May 21, 2015 from the ... was below certain of the Exchange,s continued listing standards, ... the NYSE MKT Company Guide, due to the delay ...
Breaking Medicine Technology:IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... MISSISSAUGA, Ontario, June 22, 2011 CardioGenics Holdings ... magnetic beads business unit, which develops ultra sensitive ... its Canadian subsidiary, Luxspheres Inc. The beads business ... Company,s CardioGenics Inc. Canadian subsidiary ("CardioGenics"), will now ...
... N.J., June 22, 2011 ... Co. Ltd., and an international specialty pharmaceutical company, today ... Food and Drug Administration (FDA) for Rectiv™ (nitroglycerin) Ointment ... pain associated with chronic anal fissures.  Rectiv will be ...
Cached Medicine Technology:CardioGenics Transfers Magnetic Beads Business Unit Into its Luxspheres Inc. Subsidiary 2CardioGenics Transfers Magnetic Beads Business Unit Into its Luxspheres Inc. Subsidiary 3ProStrakan Receives FDA Approval for Rectiv™ for the Treatment of Moderate to Severe Pain Associated With Chronic Anal Fissures 2ProStrakan Receives FDA Approval for Rectiv™ for the Treatment of Moderate to Severe Pain Associated With Chronic Anal Fissures 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: